BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-… Read more
BioNote Inc. (377740) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: -0.009x
Based on the latest financial reports, BioNote Inc. (377740) has a cash flow conversion efficiency ratio of -0.009x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-14.45 Billion) by net assets (₩1.55 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioNote Inc. - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how BioNote Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioNote Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNote Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenland Resources Inc
PINK:GRLRF
|
-0.139x |
|
LONGBOAT ENERGY LS-10
F:8YG
|
N/A |
|
Taiwan Kong King Co Ltd
TWO:3093
|
0.115x |
|
ChainSea Information Integration Co.,Ltd.
TWO:6898
|
0.142x |
|
Betmakers Technology Group Ltd
PINK:TPBTF
|
-0.076x |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
0.085x |
|
Alpha Technology Group Limited Ordinary Shares
NASDAQ:ATGL
|
-0.326x |
|
Zenix Robotics Co.,Ltd
KQ:381620
|
-0.075x |
Annual Cash Flow Conversion Efficiency for BioNote Inc. (2019–2022)
The table below shows the annual cash flow conversion efficiency of BioNote Inc. from 2019 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | ₩1.60 Trillion | ₩249.10 Billion | 0.156x | -63.31% |
| 2021-12-31 | ₩1.27 Trillion | ₩537.39 Billion | 0.424x | +12.96% |
| 2020-12-31 | ₩638.70 Billion | ₩239.93 Billion | 0.376x | +321.65% |
| 2019-12-31 | ₩110.58 Billion | ₩9.85 Billion | 0.089x | -- |